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with or without surgery
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Chad Zender, MD4, Laura Doyle, MS2, David Kutler, MD5, Benjamin Leiby, PhD6, William Keane, MD1, Adam Luginbuhl, MD1
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4Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 5Department of Otolaryngology, Weill Cornell Medical
Center, New York, NY, 6Department of Biostatistics, Thomas Jefferson University, Philadelphia, PA, USA

Abstract
Purpose: To review brachytherapy use in recurrent head and neck carcinoma (RHNC) with focus on its efficacy
and complication rates.
Material and methods: A literature search of PubMed, Ovid, Google Scholar, and Scopus was conducted from 1990
to 2017. Publications describing treatment of RHNC with brachytherapy with or without surgery were included. The
focus of this review is on oncologic outcomes and the safety of brachytherapy in the recurrent setting.
Results: Thirty studies involving RHNC treatment with brachytherapy were reviewed. Brachytherapy as adjunctive treatment to surgical resection appears to be associated with an improved local regional control and overall
survival, when compared with the published rates for re-irradiation utilizing external beam radiotherapy (RT) or
brachytherapy alone. Safety data remains variable with different isotopes and dose rates with implantable brachytherapy demonstrating a tolerable side effect profile.
Conclusions: Although surgery remains a mainstay treatment for RHNC, intraoperative interstitial brachytherapy
delivery as adjunctive therapy may improve the treatment outcome and may be associated with fewer complication
rates as compared to reirradiation using external beam radiotherapy. Further investigations are required to elucidate
the role of brachytherapy for RHNC.
J Contemp Brachytherapy 2018; 10, 5: 454–462
DOI: https://doi.org/10.5114/jcb.2018.79399
Key words: cesium, head and neck cancer, recurrent.

Purpose
Head and neck carcinoma (HNC) continue to be a commonly diagnosed cancer with almost 50,000 new cases and
almost 10,000 deaths each year [1]. More than 90% of HNC
are classified as squamous cell carcinoma, and cases have
increased by nearly 5,000 new patients over two years [2,3].
Patients with locally advanced disease generally are treated with an algorithm of surgical resection, radiotherapy
(RT), and/or chemoradiotherapy with curative intent. Unfortunately, depending on subsite and stage, almost half of
these advanced stage patients fail this approach in the first
5 years [4,5]. The predominant pattern of recurrence is in
a locoregional manner [5]. Surgical resection for these patients has become the mainstay of treatment in resectable
cases, and re-irradiation as the only locoregional treatment
modality for unresectable cases.

Brachytherapy with or without salvage surgery has
often been used for this group of cancer patients with
RHNC. Compared to external beam radiation therapy
(EBRT) delivery systems, including intensity modulated radiation therapy (IMRT) and proton beam therapy,
brachytherapy offers focused dose delivery and fewer
early toxic effects, while minimizing adjacent non-cancer
tissue toxicity, specifically in previously irradiated fields
[5]. This protection of adjacent normal tissue can result in
preservation of laryngeal and tongue function. Although
brachytherapy has been utilized for recurrent head and
neck cancer (RHNC) for years, its use has been limited
due to availability of technical expertise, variable isotope
implantation technical issues, and introduction of IMRT
and other alternative EBRT modalities. Brachytherapy
can be delivered via permanent implants (using low-doserate brachytherapy or LDR or high-dose-rate brachyther-
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apy or HDR) or via removable catheters through which
typically high activity radioisotopes are inserted (using
HDR or pulsed-dose-rate brachytherapy or PDR) [6]. Permanent implants may be advantageous in patients with
recurrence in irregular surfaces that are not suitable for
catheter-based isotope delivery [7]. This review describes
brachytherapy efficacy in recurrent primary HNC and recurrence in neck disease, and potential complications of
brachytherapy. We separated studies based on whether
brachytherapy was the sole treatment or in conjunction
with surgical tumor resection.

Material and methods
A literature search using PubMed, Ovid, Google
Scholar, and Scopus was conducted. Databases were
searched for the terms ‘recurrent head and neck cancer’
AND ‘brachytherapy’ between 1990 and 2017. Additional
search terms included ‘Cesium-131’, ‘Iridium-192’, and
‘Iodine-125’. The general criteria for the studies to be included were publications describing brachytherapy use
in recurrent HNC of various sites, with particular focus
on treatment outcomes and complications. Publications
involving 131Cs brachytherapy are also described. The
search identified a total of 380 papers, with 350 papers
being excluded after title and abstract screening. In
these excluded papers, brachytherapy in recurrent HNC
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of various sites was not the chief focus. The remaining
30 studies reported adequate information according to the
criteria. Statistical analysis was also performed to compare recurrence rates in studies, which used brachytherapy with surgery versus brachytherapy alone.

Results
In the 30 reviewed studies, 95% (1,440 of 1,515 patients)
had prior radiation therapy, making radiotherapy treatment options limited. In 23 of these studies, brachytherapy was administered using Iridium-192 (192Ir) in 1,003
patients, Iodine-125 (125I) in 131 patients, and Cesium-131
(131Cs) in 35 patients. Seven studies did not explicitly
state which type of isotope was used [8,9,10,11,12,13,14].
Brachytherapy was incorporated into treatment planning
with or without salvage surgery in a combined modality
approach. Occasionally, brachytherapy was also followed
by further radiation therapy or chemotherapy. Reirradiation with brachytherapy was used for local, locoregional,
or nodal recurrence or neck disease and not for distant
metastatic spread. As with most forms of reirradiation,
the toxicity profile of brachytherapy includes neurologic
toxicity, dysphagia, carotid artery rupture, skin necrosis,
fistulas, and osteoradionecrosis [15,16]. These aspects
and other considerations within the studies are described
in further detail below.

Table 1. Overview of studies treating recurrent head and neck squamous cell carcinoma using brachytherapy
alone
Author, Year

N

Brachytherapy

Total dose

Additional therapy

Results

Complications

Grimard,
2006 [5]

82

Ir 192; LDR

≥ 55 Gy

Surgery (14),
EBRT (3),
Surgery + EBRT (6)

LC at 2 years: 37%
OS at 2 years: 33%

8.5% acute toxicity
22% late toxicity

Strnad,
2014 [8]

104

PDR

55 Gy or 24 Gy
(when +EBRT)

Surgery (51%),
EBRT (32%),
Chemo (56%)

LC at 5 years: 82%
OS at 5 years: 21%

31% late toxicity

Strnad,
2014 [12]

51

PDR

60 Gy or 27 Gy
(when +EBRT)

EBRT (22%),
Chemo (69%)

LC at 5 years: 57%

10% acute grade 3
29% late toxicity

Puthawala,
2001 [17]

220

Ir 192; LDR

Median: 53 Gy

Chemo (88)

LC at 5 years: 51%
OS at 5 years: 20%

60% acute toxicity
27% late toxicity
(65% of which had RT
> 65 Gy)

Hepel,
2005 [18]

30

Ir 192; HDR

Mean: 34 Gy

Chemo (43%),
EBRT (6%)

LC at 2 years: 67%
OS at 2 years: 37%

16% late grade 3-4
toxicity

Jiang,
2011 [19]

29

I 125; LDR,
US-guided

Median: D90 130 Gy

Not mentioned

LC at 2 years: 35%
OS at 2 years: 28%

No carotid rupture
or soft tissue/bone
necrosis

Glatzel,
2002 [37]

90

Ir 192; HDR

Median: 17.5 Gy

Not mentioned

Median: OS 6 Mo

7% late grade 3-4

Zhu,
2013 [32]

19

I 125; LDR,
US or CT-guided

Median: D90 131 Gy

Not mentioned

LC at 2 years: 27.5%
OS at 2 years: 18%

No grade 4 or
5 toxicity

Meng,
2012 [38]

17

I 125; LDR,
Median: D90 126 Gy
US or CT-guided

Not mentioned

LC at 2 years: 50%
OS at 2 years: 24%

No grade 3 or
4 toxicity

Wiegand,
2013 [39]

12

Not mentioned

Median: OS 8.5 Mo

No serious complications

Ir 192; HDR

Mean: 20-33 Gy

Ir 192 – Iridium 192; I 125 – Iodine 125; Gy – Gray; LDR – low-dose-rate; HDR – high-dose-rate; PDR – pulsed-dose-rate; US – ultrasound; CT – computed tomography;
EBRT – external beam radiation therapy; RT – radiotherapy; LC – local control; OS – overall survival

Journal of Contemporary Brachytherapy (2018/volume 10/number 5)

Julianna Rodin, Voichita Bar-Ad, David Cognetti, et al.

456

Brachytherapy for local disease:
with and without salvage surgery
Re-irradiation with brachytherapy has been used as
an option for resectable and unresectable RHNC cases.
While salvage surgery in general is favored, its use may
be limited by the extent of disease and the cancer’s intimate anatomic relationship to adjacent structures. Lowdose-rate (LDR), high-dose-rate (HDR), and pulsed-doserate (PDR) brachytherapy can be used as monotherapy
alone or adjuvantly with salvage surgery. Tables 1 and 2
provide details of all studies using brachytherapy alone
and with surgery, respectively. Some of these studies are
further described below.
The use of brachytherapy alone was associated with
lower local control (LC) and overall survival (OS) rates. In
a study by Puthawala et al. [17], 220 patients with RHNC
received salvage brachytherapy using LDR interstitial
Iridium-192 (192Ir) implants. They achieved 2-, 5-, and
10-year disease-free survival (DFS) rates of 60%, 33%, and
22%, respectively [17]. Hepel et al. [18] found similar results using HDR 192Ir brachytherapy with DFS at 2 years

being 45% and OS at 1 and 2 years, 56% and 37%, respectively. Strnad et al. [8] found that their LC rates at 2, 5, and
10 years were 92.5%, 82.4%, and 58.9%, respectively, with
a 5-year OS of 21% using PDR brachytherapy. Jiang et al.
[19] used LDR 125I ultrasound-guided permanent seeds in
patients with RHNC ineligible for salvage surgery, and
achieved LC rates at 1, 2, and 3 years of 53.1%, 34.8%, and
17.4%, and OS rates at 1, 2, and 3 years of 54.1%, 27.5%,
and 27.5%, respectively.
In the recurrent setting, surgical resection remains
the foundation of treatment for resectable disease, when
looking at oncologic outcomes. In a study by Grimard et
al. [5], brachytherapy was used as monotherapy in 22 of
45 patients and with surgery in 20 of 45 patients [5]. While
not statistically significant, salvage surgery with adjuvant brachytherapy led to better locoregional control [5].
Narayana et al. [9] studied patients with recurrent HNC
with 18/30 receiving surgery and HDR, 3/30 receiving
EBRT and HDR, and 9/30 receiving HDR alone. There
was improved local control in patients who received salvage surgery versus those without surgery: 88% vs. 40%
[9]. In a study by Rudzianskas et al. [20], 43% of patients

Table 2. Overview of studies treating recurrent head and neck squamous cell carcinoma using surgery with
brachytherapy
Author, year

N

Brachytherapy

Total dose

Surgical
resection

Results

Complications

Henderson,
2016 [6]

23

Ir 192; HDR
Cs-131; LDR

Mean: 21 Gy
Mean: 81 Gy

Yes

Not mentioned

50% toxicity in HDR pts
30% toxicity in LDR pts

Narayana,
2007 [9]

30

HDR

34 Gy (+ surgery)
20 Gy (+ EBRT)
40 Gy (only BT)

60% Yes
40% No

LC at 2 years: 71%
(88% + surgery,
40% – surgery)
OS at 2 years: 63%

33% grade 2-3 toxicity

MartinezFernandez,
2017 [10]

63

HDR

Total: 32 or 40 Gy

Yes

LC at 15 years: 41%
OS at 15 years: 12%

51% grade ≥ 3 toxicity

Schiefke,
2008 [11]

13

HDR

Median: 30 Gy

Yes

OS at 2 years: 65%
LR failure in 38%

69% acute toxicity
31% late toxicity

Scala,
2013 [13]

76

HDR

Median rate: 1,200 cGy

Yes

LC at 2 years: 62%
OS at 2 years: 42%

No grade 3-4 toxicity

Rudzianskas,
2012 [20]

30

Ir 192; HDR

Total: 30 Gy

43% Yes
57% No

LC at 2 years: 77%
OS at 2 years: 62%
Non-surgical group:
LC at 2 years: 47%
OS at 2 years: 35%

10% acute grade 2-3
10% late grade 2-4

Park,
1991 [21]

35

I 125; LDR

Mean rate:
8,280 cGy

Yes

OS at 2 years: 38%
OS at 5 years: 29%

36% acute and/or late
toxicity

Pellizzon,
2005 [22]

42

Ir 192; HDR

Median: 24 Gy

Yes

Crude LC 57%
OS at 5 years: 52.5%

19% acute and/or late
toxicity

Pham,
2015 [23]

18

Cs 131; LDR

Median: 80 Gy

Yes

OS at 18 mos: 45%
LR failure in 33%

11% grade 3 toxicity

Teckie,
2013 [41]

57

Ir 192; HDR

Median: 15 Gy

Yes

OS at 3 years: 32%
LR failure in 46%

37% grade 3
No grade 4-5 toxicity

Perry,
2010 [42]

34

Ir 192; HDR

Median: 15 Gy

Yes

OS at 2 years: 55%

29% grade 3-4 toxicity

Ir 192 – Iridium 192; I 125 – Iodine 125; Cs 131 – Cesium 131; Gy – Gray; LDR – low-dose-rate; HDR – high-dose-rate; EBRT – external beam radiation therapy;
BT – brachytherapy; LC – local control; LR – locoregional; OS – overall survival
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had surgery and HDR with 192Ir, while 57% had HDR
alone. Patients who received surgery and brachytherapy had improved 2-year local control rates (77%) and OS
rates (62%) versus those with brachytherapy alone (47%,
35%, respectively) [20]. These differences in locoregional
control underscore the overall benefit of surgical resection in the recurrent setting.
In a study by Park et al. [21], LDR 125I seeds were implanted in patients with RHNC who all underwent salvage surgery. DFS at 1, 2, and 5 years was 64%, 47%, and
41%, respectively, with a 5-year no evidence of disease
(NED) in patients (29%) [21]. Pellizzon et al. [22] studied patients with RHNC treated with surgery and HDR
192Ir brachytherapy with or without further EBRT and
found the OS at 5 and 8 years to be 52.5% and 48.1%.
Martinez-Fernandez et al. [10] followed previously irradiated RHNC patients treated with salvage surgery and
perioperative HDR brachytherapy for 15 years, finding
a 15-year LRC rate of 41.2% and 15-year OS rate of 11.6%.
Pham et al. [23] showed that in selected patients, 131Cs intraoperative seeds with salvage surgery achieved 1-, 2-,
and 3-year LC rates of 69%, 62%, and 52%, respectively.
Looking to historic data of re-irradiation using the
standard or hyperfractionated IMRT combined with systemic chemotherapy has demonstrated a 2-year survival
of 10-25% [24,25]. The previously discussed studies using surgery plus brachytherapy reported a 5-year overall
survival of 33-67%, showing encouraging progress over
EBRT plus chemotherapy.
We performed a statistical analysis of the studies to
evaluate locoregional recurrence in RHNC patients receiving brachytherapy and surgery vs. brachytherapy
alone. Logistic regression was used to compare recurrence rates, and generalized estimating equations (GEE)
methods were used to account for clustering within the
study. In studies where recurrence rates were not explicitly stated, recurrence rates were extrapolated based on
the local and locoregional control rates. For the primary
analysis, the rate of locoregional recurrence was 38.8%
(143/369) in the surgery with brachytherapy group and
49.0% (329/671) in the brachytherapy alone group. The
estimated odds ratio was 0.66 (95% CI: 0.38-1.12; p = 0.13).

Brachytherapy for nodal disease
Many studies also have demonstrated brachytherapy
use in RHNC with regional failure in the cervical lymph
nodes. Table 3 portrays the details of these studies. In the
study by Bartochowska et al. [26], patients with unresectable isolated cervical lymph node recurrence had PDR or
HDR with 192Ir via catheters. Local control rates at 1 and
2 years were 31.7% and 19% [26]. Huang et al. [27]
achieved better results in 31 patients with RHNC with
neck metastases unmanageable with other techniques,
achieving LC rates of 64.5% and 45.1% at 1 and 2 years. In
74 patients with inoperable recurrent lymphadenopathy,
Tselis et al. [28] showed OS rates of 42%, 19%, and 6% at
1, 2, and 3 years, respectively.
In the study by Teudt et al. [14], patients with RHNC
underwent revision surgery and perioperative HDR for
their recurrent neck metastases. These patients were
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found to have 78% and 67% OS at 2 and 5 years, respectively, with a median survival of 65 months [14]. Nutting
et al. [29] also looked at patients with recurrent neck disease undergoing LDR brachytherapy alone, with resection, or with resection and flap surgery. Locoregional
control at 2 years in those who had brachytherapy alone
was 0%, while those who also had a surgery with or without a flap had improved LRC, 37% or 33%, respectively
[29]. For the neck disease statistical analysis, the rate of
locoregional recurrence was 30.9% (42/136) in the surgery with brachytherapy group and 49.0% (149/304) in
the brachytherapy alone group. The estimated odds ratio
was 0.46 (95% CI: 0.25-0.86; p = 0.015).

Complications
Due to the nature of the radioactive isotopes,
brachytherapy is associated with various radiation exposure concerns. However, these radiation effects appear to
be improved in terms of functional organ preservation
and reduced irradiation to surrounding normal tissues
compared to EBRT or IMRT (Quon). Toxicity is commonly monitored using the Radiation Toxicity Oncology
Group (RTOG) common toxicity criteria [30]. Radiation
safety procedures, including the use of lead shields and
gloves, may be appropriate when handling specific radioisotope implants, which is based on a number of factors
including isotope, total source activity, and implant location [31]. The recommended limit of radiation exposure
to staff personnel based on federal regulation is 50 mSv/
year for “stochastic effects”, e.g., cancer or genetic effects,
defined as “ones in which the probability of occurrence
increases with increasing absorbed dose, but the severity
does not depend on the magnitude of the absorbed dose”
[31]. In some cases associated with specific radioisotopes,
patients were isolated in order to reduce personnel and
family radiation exposure, and were required to stay in
the hospital longer.
Toxicity complications related to brachytherapy have
been explored in various studies using 192Ir and 125I and
usually involve necrosis, dysphagia, or fistulas. Tables
1-3 include toxicity rates for studies reviewed. In a review
by Kasperts et al. [15], 17% (120/704) of patients developed soft tissue necrosis and 2% (15/704) developed orocutaneous fistulas. Another 2% of patients suffered from
hemorrhage or carotid blowouts and another 3% developed osteoradionecrosis [15]. In the study by Grimard et
al. [5], acute toxicity occurred in 15.6% of patients and late
toxicity in 40%, with 4 patients developing grade 2 or 3
radionecrosis and 7 patients experiencing dysphagia. In
Zhu et al.’s study [32], only one patient had a grade 1 skin
reaction, with no patients suffering from soft tissue necrosis or other complications. Henderson et al. [6] looked
at patients who underwent HDR or LDR brachytherapy
and neck dissection with or without flap coverage. There
were complications in 50% of HDR patients and 29.4% of
LDR patients, with only 3 of 22 patients receiving flaps
having complications (2 HDR, 1 LDR) [6]. Martinez-Fernandez et al. [10] found RTOG grade 3 or greater toxicities
in 50.8% of patients, with 17 cases needing further operations due to fistula (6), wound dehiscence (4), bleeding (3),
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Table 3. Overview of studies treating recurrent squamous cell carcinoma as neck disease
Author, year

N

Brachytherapy

Total dose

Surgical
resection

Results

Complications

Bartochowska,
2015 [26]

60

Ir 192;
PDR (49 pts) or
HDR (11 pts)

Median: 20 Gy or 24 Gy

No

LC at 2 years: 27%
OS at 2 years: 19%

33% acute toxicity
12% late toxicity

Huang,
2016 [27]

31

I 125; LDR,
CT-guided

Mean: D90 101 Gy

No

LC at 2 years: 45%
OS at 2 years: 45%

No grade 3 or 4 toxicity

Tselis,
2011 [28]

74

Ir 192;
HDR, CT-guided

Median: 30 Gy

No

LC at 2 years: 67%
OS at 2 years: 19%

5% acute grade 3-4 toxicity
8% late grade 3-4 toxicity

Kolotas,
2007 [43]

49

Ir 192;
HDR, CT-guided

Total: 30 Gy or 36 Gy

No

LC at 19 mos: 69%
OS at 2 years: 31%
OS at 3 years: 6%

16% acute grade 2-3 toxicity

Bollet,
2001 [44]

84

Ir 192; LDR

Mean: 56.5 Gy

No

LC at 2 years: 31%
LC at 5 years: 0%
OS at 2 years: 13%
OS at 5 years: 1%

35% grade 3-4 toxicity
7% grade 5 (death)

Brachytherapy combined with surgical resection
Teudt,
2016 [14]

9

HDR

Mean: 27 Gy

Yes

OS at 2 years: 78%
OS at 5 years: 67%

No grade 3 or 4 toxicity

Kupferman,
2007 [24]

22

Ir 192; LDR

Median: 60 Gy

Yes

RC at 2 years: 67%
OS at 5 years: 46%

14% acute grade 3-4 toxicity
18% late grade 3-4 toxicity

Nutting,
2006 [29]

72

Ir 192; LDR

Total: 60 Gy

Yes in 66
No in 6

LC at 5 years: 23%
OS at 5 years: 23%
Non-surgical group:
LC at 2 years: 0%
OS at 2 years: 0%

15% grade 3-4 toxicity

Cornes,
1996 [40]

39

Ir 192; LDR

Mean: 49.6 Gy

Yes

LC at 1 yr: 63%
OS at 2 yrs: 38%

5% acute grade 3-4 toxicity
23% late grade 3-4 toxicity

Ir 192 – Iridium 192; I 125 – Iodine 125; Gy – Gray; LDR – low-dose-rate; HDR – high-dose-rate; PDR – pulsed-dose-rate; CT – computed tomography; LC – local control;
RC – regional control; OS – overall survival

or other (4). Notably, many forms of brachytherapy did
not use permanent implantable seeds but temporary
catheters for the purpose of low-dose or high-dose-rate
brachytherapy. Hemorrhage after catheter or tube removal was reported [15].
In contrast, Pham et al. [23] reported similar or lower
rates of acute and chronic toxicity with 131Cs as compared
to studies using 192Ir and 125I. Only 2 of 18 patients had
grade 3 toxicity and none had grade 4-5 toxicity. When
present, grade 1-2 complications were primarily dermatitis and hoarseness [23]. The risk to healthcare personnel
and close family members has been minimized with isotopes like 131Cs compared to some previous brachytherapy isotopes, which required special precautions [31].
Many prior studies portrayed the effects of 125I and 192Ir
brachytherapy on RHNC, but fewer studies have explored the use of permanent 131Cs. 131Cs offers a highdose-rate, focused delivery, and less radiation exposure
to adjacent tissues, personnel, and the patient’s family
[23,31]. Compared to 125I, 131Cs has a dose-rate several
times higher because of its similar energy but much lower half-life (9.69 days) [33]. This allows for 131Cs to deliver
~90% of its dose in a 33-day period, unlike 32% of the
dose delivered by 125I in that time frame [33]. This longer
period of time exposes staff and family to potentially in-

creased radiation doses and may require special precautions. Suture strands containing 131Cs seeds can be fixed
0.5-1 cm apart within the tumor bed or come in a pre-imbedded mesh (Figure 1) [31]. With brachytherapy done
during salvage surgery, flaps also may help to prevent
seed migration and dosimetry alterations. After implantation, seed placement can be monitored radiographically
by generating a post-implant plan and toxicity monitored
using RTOG common toxicity criteria [30]. In a study by
Parasher et al. [31], 28 patients received a median number
of twenty 131Cs seeds implanted at 0.5-1 cm distance for
lung or HN cancer, with a median seed activity of 2.4 U.
Median radiation exposure rate at the skin and at 1 meter was 0.43 mSV and 0.002 mSv, respectively. Minimum
measurable radiation dose for OSL badge and TLD ring
was 1 mrem and 30 mrem [31]. These minimal dose levels
allow for patients to interact with family members and
caregivers without special precautions like special lead
protective equipment or isolation.

Discussion
Treatment options for RHNC remain limited. Many
patients have undergone previous surgeries with or
without radiation, chemotherapy, immunotherapies,
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B

Fig. 1. A) Post-operative radiographic Cesium-131 seed
dosimetry. B) Cesium-131 seed placement intra-operatively

and/or combination therapies, which limit retreatment
options with radiation in general and EBRT in particular. The most common current treatment for curative
intent is salvage surgery but may not be feasible for all
cases [34,35,36]. Despite wide margins and G0 resection,
locoregional recurrence still thwarts the curative efforts
in the recurrent setting. Adding focused radiation directed at the resection margin during salvage surgery,
while sparing toxicity to surrounding tissue, is in theory
promising.
Brachytherapy has shown to be an effective treatment
option with acceptable toxicity profiles for RHNC. When
using brachytherapy alone, the reported LR control rates
and OS rates at 2 years range from 27.5-92.5% and 18.243%, respectively [5,8,12,17,18,19,32,37,38,39]. Some studies have revealed brachytherapy to have enhanced and
improved results when combined with salvage surgery
[9,20,29,40]. Salvage surgery with brachytherapy as adjunctive therapy has 2-year LR control rates and OS rates
ranging from 62-88% and 38-65.3%, respectively [6,9,10,11,
13,20,21,22,23,41,42]. Studies by Narayana et al. and Rudzianskas et al. even compared LC and OS rates at 2 years
between those who received brachytherapy with and
without surgery and found improved rates in those also
receiving surgery [9,20]. Although our analysis comparing
locoregional recurrence rates of patients receiving surgery
with brachytherapy vs. brachytherapy alone was not statistically significant, there was a trend of 38.8% vs. 49.0%.
For brachytherapy use in patients with neck disease, LC

and OS rates at 2 years had likewise fair responses, with
rates ranging from 27.3-67% and 13-78%, respectively
[14,24,26,27,28,29,40,43,44]. Many of these studies had recurrent HNC with neck metastases that appeared inoperable or unmanageable with other therapies. Yet, analysis in
these neck disease patients did show a statistically significant difference (p = 0.015) in locoregional recurrence rates
(30.9% vs. 49.0%) between the combined treatment group
and brachytherapy alone group, respectively.
In comparison, a review by Goodwin [34] described
outcomes using salvage surgery alone, the most common
salvage treatment. The weighted average of OS at 3 years
was 37% (range: 28-80%) and at 5 years was 36.4% (range:
23-55%) [34]. Goodwin [34] also reported the weighted
average of disease-free survival (DFS) rates at 2 years:
36.3% (range: 0-59%). Moreover, a literature review by
Strojan et al. [35] examined local control and survival
rates using conventional EBRT techniques and newer
EBRT techniques like IMRT, with or without surgery, in
recurrent HNC. Locoregional control rates and OS rates
at 2 years using conventional radiation techniques with
salvage surgery ranged from 13-74% (average: 38%)
and 21-67% (average: 42.5%), respectively [35]. Newer
RT techniques like IMRT have been showing better outcomes. For example, a study by Lee et al. [36] did show
that IMRT had improved LR recurrence-free survival at
2 years over conventional RT techniques (52% vs. 20%)
but did not significantly improve OS rates. In general,
for patients receiving IMRT (with or without salvage
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surgery), LR control and OS rates at 2 years ranged from
27-77% and 19.5-58%, respectively [35,45].
Similarly, to some brachytherapy studies, patients receiving reirradiation (either using conventional or newer
RT techniques) with salvage surgery had improved outcomes. One phase III randomized trial by Janot et al. [46]
divided patients into receiving salvage surgery alone or
with adjuvant full-dose reirradiation with chemotherapy.
Patients in the radiation arm (using conventional RT) had
significantly improved LR control and DFS rates but no
significant change in OS rates at 2 years [46]. Likewise,
a study by Takiar et al. [47] showed improved disease
control and survival outcomes using adjuvant IMRT after surgery (vs. surgery alone) in HNSCC patients with
a 5-year OS rate of 57%.
Complications appear less frequent or severe compared to EBRT techniques including IMRT. In some
brachytherapy studies, complication rates ranged as
high as 50-60% for acute grade 1-2 toxicities including
mucositis, dermatitis, hoarseness, infection, or hematoma [12,14,17,26,27]. Late grade 3-4 toxicities included
complications like fistula, soft tissue necrosis, ORN, dysphagia, fibrosis, trismus, severe hemorrhage, and wound
dehiscence, with rates ranging from 7-51% [9,10,12,17,
18,20,21,28,29,37,40,42]. In the study by Takiar et al. [47]
using IMRT for re-irradiation, there was a 5-year grade
≥ 3 toxicity rate of 48%, with three patients dying due
to radiation toxicity. However, the majority of patients
who now are receiving their first round of radiation with
IMRT may likely have fewer overall complications, if or
when they receive reirradiation. Literature is limited at
this time to support this theory but will likely be shown
in coming years.

We propose an algorithm to help guide treatment options for patients with RHNC (Figure 2). For example, for
patients with resectable locoregional recurrence, consider surgical resection followed by brachytherapy or EBRT
with or without chemotherapy or immunotherapy. Using
brachytherapy versus external radiation techniques like
IMRT may depend on the timing, type of previous RT,
and location of recurrence. Despite the safety, ease of use,
and promising efficacy advantages of 131Cs, the use for
specific RHNC populations requires further investigation. Unfortunately, the majority of published literature
is retrospective, and the patient cohorts and treatment
approaches used are very heterogeneous. In theory, combining a radiation boost to salvage surgery may provide
dual therapy with less radiotherapy toxicity. 131Cs with
salvage surgery and other combinations with immunotherapy may offer a viable treatment pathway for RHNC
for some patients and should be studied in future clinical
trials. Our institution has recently been studying 131Cs
brachytherapy in RHNC with preliminary promising results. At this time, HDR and PDR appear to be the current
techniques of choice due to optimization of implant dosimetry and geometric sparing with and reduced treatment time.

Conclusions
Treatment options for RHNC remain challenging.
Although brachytherapy alone can be used to treat
RHNC, locoregional control rates and overall survival
rates are higher when brachytherapy is used as adjunctive therapy to salvage surgery. These rates remain comparable or improved when brachytherapy is utilized in

Resectable

Locoregional
recurrence

Non-resectable
Recurrent head
and neck squamous
cell carcinoma

Distant
metastases

Previous radiation
precludes further
EBRT

Surgical resection +
brachytherapy

No previous
radiation or prior
radiation > 1 year

Surgical resection
followed by IMRT
± Chemo/IT

Primary treatment
including EBRT
< 12 months prior

Consider systemic
therapy

Primary treatment
including EBRT
> 12 months prior

Consider Chemo/IT
+ IMRT

With
locoregional failure

Consider systemic
therapy ± locore
gional treatment

Without
locoregional failure

Consider systemic
therapy

Standard
chemotherapy
regimen
Immunotherapy
(i.e. PD-1 inhibitors)

Fig. 2. Proposed algorithm for treating recurrent head and neck squamous cell carcinoma
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neck disease with or without surgery. Regardless of the
type of radiotherapy used, these patients continue to
face significant risks for recurrence and complications
including fistula formation, carotid rupture, dysphagia, osteoradionecrosis, and prolonged hospital stay
[9,10,20,21,42,48,49,50]. With the recent introduction of
isotopes with more favorable properties, complication
rates have the potential to be lower while preserving local regional control rates.
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